Clinical Trial: CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma

U.S., Sept. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07830485) titled 'CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma' on Sept. 15.

Brief Summary: The goal of this clinical trial is to evaluate whether CM336, a BCMA/CD3 bispecific antibody, in combination with daratumumab and lenalidomide can induce deep and durable responses in adults with transplant-ineligible newly diagnosed multiple myeloma (NDMM). The study will also evaluate the safety of this treatment combination.

The main questions it aims to answer are:

* How many participants achieve minimal residual disease (MRD) negativity after 6 treatment cycles?

* What side effects occur during trea...